NorwayNorway

Fish Genomics Consortium

13.11.2004

Oslo - FUGE, the Norwegian national programme for research in functional genomics, will co-ordinate Norwegian research concerning the genomics of fish, starting with salmon and cod.
FUGE has already acquired a salmon biobank from Genomar ASA, based in Oslo, and also aims at building one for cod in order to put Norway in a leading position in fish genomics.

NorwayNorway

08.03.2012

With a bold approach, including next-generation DNA sequencing (NGS) and state-of-the-art biobanking systems, Norway is pushing forward personalised cancer treatments in its national health care system. Clinical-quality genome...

NorwayNorway

06.03.2012

Bionor Pharma ASA’s development of an HIV vaccine is back on track. In mid-February, the Oslo-based company announced positive results from a Phase IIb study. When combined with antiretroviral treatment, the Vacc-4x vaccine...

NorwayNorway

19.01.2012

Oslo – The north lights up with financial flares. Norwegian cancer specialist Clavis Pharma ASA has raised €21m through a placement of new shares. The 2.8 million shares represent approximately 9.4% of the current stock in the...

NorwayNorway

11.01.2012

Bergen – BerGenBio A/S announced it has completed an €6.9m Series A financing round. The money will be spent in taking their lead compound BGB324 into clinical trials and to develop a companion diagnostic. The lead investors are...

NorwayNorway

13.12.2011

Reykjavik – Iceland’s deCODE Genetics, which Arch Venture Partners and Polaris Venture Partners lifted out of bankruptcy in January 2010, has been making a comeback of late. In mid-October, the genome analyser announced it had...

NorwayNorway

01.10.2011

Oslo/Leverkusen – Norwegian radiotherapy specialist Algeta ASA and German drugmaker Bayer have presented new data on their cancer drug alpharadin. The radium-223-chloride pharmaceutical showed an increased overall survival rate...

NorwayNorway

30.09.2011

Lysaker/Osaka - Pronova Biopharma SA is set on entering the Japanese market with its TAK-085 (omega-3-acid ethyl esters 90) for the treatment of hyperlipidemia. Pronova's partner Takeda Pharmaceutical Company Limited submitted a...

NorwayNorway

14.06.2011

Laskut/Berlin – Researchers from Finland’s Technical Research Center VTT and the Charité Hospital in the German capital have come a step closer to a personalised diagnostic test for cancer. Matej Orešic (VTT) and Carsten Denkert...

NorwayNorway

12.06.2011

Oslo – Norwegian cancer drug development company Clavis Pharma ASA will receive a grant from the Norwegian government for the development of a companion diagnostic in acute myeloid leuk­aemia (AML). The Research Council of Norway...

NorwayNorway

17.05.2011

Oslo – Clavis Pharma ASA has signed a licensing deal with US firm Translational Therapeutics, Inc., for the development and commercialization of CP-4033, a patented Lipid Vector Technology (LVT) derivative of ribavirin under...

Displaying results 1 to 10 out of 92

1-10 Next >

© 2007-2015 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-norway/article/fish-genomics-consortium.html

WhitePaper

LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...

Product of the week

Products

Events

All Events

Partner-Events

Frankfurt am Main (DE)

ACHEMA 2015

Stock list

All quotes

TOP

  • CHRONTECH PHARMA (S)0.02 SEK100.00%
  • NEOVACS (F)1.25 EUR15.74%
  • SCANCELL HOLDINGS (UK)38.25 GBP14.18%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)22.00 SEK-53.97%
  • ANTISOMA (UK)1.00 GBP-35.48%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%

TOP

  • CHRONTECH PHARMA (S)0.02 SEK100.0%
  • HYBRIGENICS (F)1.86 EUR44.2%
  • GALAPAGOS (B)51.13 EUR36.1%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)22.00 SEK-56.7%
  • CYTOS (CH)0.61 CHF-39.6%
  • ANTISOMA (UK)1.00 GBP-35.5%

TOP

  • CELLECTIS (F)38.35 EUR517.6%
  • WILEX (D)4.30 EUR465.8%
  • ADOCIA (F)69.01 EUR432.9%

FLOP

  • CHRONTECH PHARMA (S)0.02 SEK-81.8%
  • THROMBOGENICS (B)5.32 EUR-70.2%
  • ACTIVE BIOTECH (S)10.60 SEK-68.8%

No liability assumed, Date: 01.06.2015

Current issue

All issues